Companies / CytomX Therapeutics, Inc.
CytomX Therapeutics, Inc.
Nasdaq: CTMXCIK 1501989SOUTH SAN FRANCISCO, CA
Financials · FY2025
Ownership
217.9M shares outstanding · as of Jul 31, 2026
Ownership
| Insiders | 0.87% | 1,886,076 |
| 10%+ / strategic | 22.45% | 48,927,072 |
| Institutions | 56.82% | 123,817,275 |
| Public float | 19.86% | 43,268,861 |
% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.
Insiders 7
View all →| Insider | % of shares | Shares |
|---|---|---|
McCarthy Sean A.CEOCEO · Director | 0.50% | 1,078,922 |
Belvin MarciaSVP, Chief Scientific Officer | 0.14% | 300,760 |
Ogden ChristopherChief Financial Officer | 0.14% | 296,948 |
Chu Yu-WayeChief Medical Officer | 0.09% | 189,446 |
Lester RachaelChief Business Officer | <0.01% | 20,000 |
Jones Elaine VDirector | — | — |
Meyers James RDirector | — | — |
Institutional holders 133
View all →| Holder | Value | % of shares |
|---|---|---|
| $105.17M | 11.33% | |
| $66.29M | 7.14% | |
| $65.85M | 8.06% | |
| $47.46M | 4.63% | |
| $44.05M | 5.39% | |
| $38.20M | 4.11% | |
| $36.11M | 3.89% | |
| $32.77M | 3.53% | |
| $23.39M | 2.28% | |
| $22.11M | 2.38% |
Activity
Jun 30, 2026View all →
InsidersInstitutions
Who's accumulating and trimming this stock (13F).| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Q2 2026 as of | BlackRock, Inc. 13F manager | Add | — | $52.09M | +13.9M +378.55% | 17,559,822 8.06% of shares | high |
| Q2 2026 as of | State Street Corporation 13F manager | Add | — | $24.77M | +6.6M +128.50% | 11,747,236 5.39% of shares | medium |
| Q1 2026 as of | Millennium Management LLC 13F manager | Add | — | $15.84M | +3.4M +1163.65% | 3,660,190 1.68% of shares | medium |
| Q1 2026 as of | Orbimed Advisors LLC 13F manager | Exit | — | $-15.02M | -3.5M -100.00% | — | medium |
| Q1 2026 as of | Balyasny Asset Management L.P. 13F manager | Trim | — | $-14.76M | -3.1M -81.13% | 730,844 0.34% of shares | medium |
| Q1 2026 as of | Marshall Wace, LLP 13F manager | Add | — | $14.01M | +3.0M +257.68% | 4,138,176 1.90% of shares | medium |
| Q1 2026 as of | Two Sigma Investments, LP 13F manager | Add | — | $5.40M | +1.1M +73.64% | 2,710,156 1.24% of shares | medium |
| Q1 2026 as of | Baker Bros. Advisors LP 13F manager | Add | — | $3.41M | +725K +17.06% | 4,975,826 2.28% of shares | low |
5%+ ownership events
Schedule 13D / 13G
| Filer | Stance | % of class |
|---|---|---|
| State Street Corporation | Passive13G | — |
| Vanguard Group Inc | Passive13G/A | — |
| Orbimed Advisors LLC | Passive13G/A | — |
| Tang Capital Management, LLC | Passive13G/A | — |
| Fmr LLC | Passive13G/A | — |
| Kynam Capital Management, LP | Passive13G | — |
| Perceptive Advisors LLC | Passive13G/A | — |
Securities
via CUSIP / OpenFIGI
| Symbol | Type | CUSIP |
|---|---|---|
| CTMX | — | 23284F105 |